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Abstract
Background: Children born at low gestational ages face a range of risks and number of neonates surviving very
preterm birth is increasing. We present the objectives and methods of a French national cohort of very and moderately
preterm children, the EPIPAGE 2 study. It aims to examine short- and long-term outcomes of very preterm children and
their determinants.
Methods/Design: Eligible participants for this prospective population-based study include all infants live born or
stillborn and all terminations of pregnancy between 22 and 31 completed weeks of gestation in all the maternity
units in 25 French regions. In addition, a sample of moderate preterm births, i.e. births and late terminations at
32–34 weeks, was included in the same regions. In all, 7804 babies (stillbirths and live births) and terminations of
pregnancy out of 8400 eligible births in France in 2011 that were either very (22–31 weeks) or moderately preterm
(32–34 weeks) were included. Data on pregnancy, delivery, and neonatal events were extracted from the obstetric
and neonatal records. The follow-up will collect information at corrected ages of one and 2 years and at 5, 8,
and 12 years of age. Of the 4467 children discharged alive from the hospital and eligible for follow-up, 155 (4%)
families refused further follow-up and 22 died before one-year of age. Finally, 4290 were included in the follow-up.
Eight additional projects investigating specific hypotheses among subsamples of the cohort by collecting specific data
in addition to the core cohort data are being conducted to investigate 1) diagnosis of histologic chorioamnionitis, 2)
early biomarkers of child health, 3) attitudes of care for extremely preterm infants, 4) painful procedures in neonatal
intensive care units, 5) neonatal MRI cerebral abnormalities and their relation to executive functions, 6) associations
between early gut colonization and early and late onset diseases, 7) impact of neonatal nutrition on child
development, and 8) mother-infant attachment.
Discussion: This project seeks to provide new data on the prognosis and etiology of very preterm birth and to
assess related medical practices. Accordingly, it should lead to the development of new strategies of management
and prevention in high-risk babies.
Keywords: Preterm births, Cohort, Population-based study
Background
About 10 to 12% of births in the United States of America
and 5 to 7% in European countries occur before the preg-
nancy reaches term [1,2]. In France, each year, almost 35
000 babies are born between 35 and 36 weeks (4–4.5%),
13 000 between 32 and 34 weeks (1.5%), and 13 000
(1.5%) at less than 32 weeks, i.e., very preterm [2]. Preterm
birth, especially very preterm birth, is a major cause of
neonatal mortality, morbidity, and disability. Because
changes in medical practices and organization of care
continue to have a strong influence on the outcome of
these very preterm births, data about this population
require regular updating. In the absence of routine data
collection in France, population-based cohort studies are
the methodology of reference for assessing the prognosis
of high-risk children and determinants of long-term ad-
verse outcomes.
The EPIPAGE 1 study included all very preterm babies
born at 22–32 weeks in 9 French regions in 1997. It
showed that rates of hospital mortality (15%), cerebral
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lesions (26% cerebral hemorrhage and 21% white matter
damage), and disability (almost 40% of very preterm
survivors had mild to severe disability at 5 years of age)
remained high [3,4]. In recent years, European population-
based studies have been conducted in the United Kingdom
(EPICure, 1995, Trent Region, 1999–2005) [5,6], Belgium
(EPIBEL, 1999–2000) [7], and Norway (1999–2000) [8].
These studies, which have primarily focused on popula-
tions of extremely premature children and those at the
threshold of viability (less than 26 weeks gestation)
born between 1995 and 2000, showed that more than
50% died before discharge and almost 50% of survivors
developed moderate to severe disability [5,8].
The context of preterm births has changed over the
last decade. In France, the comparison of data from
EPIPAGE in 1997 with those of the MOSAIC project in
2003 for very preterm infants born between 24 and
31 weeks in the Paris area showed that the number of
live births increased by 12% and that of survivors by
20% [9]. Two population-based studies investigating
trends from the late 1990s through the early 2000s in
health outcomes of extremely preterm babies born in
Australia and the United Kingdom reported no change
in survival among babies born at 22–23 weeks [6,10].
They differed, however, in their results for babies born at
24–25 weeks. In the Trent region, UK, Field [6] reported
an increase in survival from 20% to 36% at 24 weeks and
from 47% to 59% at 25 weeks, whereas survival rates did
not change in the Australian state of Victoria [10]. The US
NICHD Neonatal Research Network reported stable
mortality between 2003 and 2007 among babies born
before 28 weeks [11]. Although differences between
countries in attitudes of care for babies born extremely
preterm may explain these differences, too little is known
about the underlying decision-making process. This aspect
needs to be investigated.
Studies of time trends for cerebral palsy and neurode-
velopmental disabilities among very preterm children
have yielded conflicting results. Data from European
registries showed that the rates of cerebral palsy and
visual deficiencies fell from the 1980s to the mid-1990s
among very preterm babies [12-15], whereas cohort
studies reported either no change or an increase [16].
Although cognitive impairment remains one of the most
serious problems among very and extremely preterm
children, no clear time trend has been identified [17].
Changes have also occurred in the organization of care
and in medical practices. In France, the National Perinatal
Program (2005–2007) has set up perinatal networks to
organize and coordinate the support and care of women
at high risk for preterm delivery, but few data evaluating
these networks are thus far available. Changes in neonatal
care include the use of new protocols, notably for neonatal
nutritional and developmental care [18]. Many pre- and
postnatal drugs (tocolytics, low-dose aspirin, sedation)
have entered general use without assessment of their long-
term effects. Structured follow-up to ensure continuing
care for very preterm babies after their discharge from the
hospital is more frequent nowadays. There is, however, no
agreement on specific protocols, and the question of
effects on longer term outcomes remains open, in view of
the weak level of evidence for the efficacy of interventions.
Finally, many questions related to the causes and conse-
quences of very preterm birth, including family burden,
must still be explored.
These changes in the prognosis and management of
very preterm infants raise multiple questions: what are
the short- and long-term consequences of very preterm
birth today? Are recent changes in medical practices
and organization of care influencing child health and
development? What are the mechanisms of long-term
adverse outcomes? Do improvements in the identifica-
tion of clinical, biological, and imaging factors help to
better predict children’s motor, cognitive, behavioral,
and health prognosis?
Accordingly, new population-based cohort studies
have recently been launched. These include EPICure 2
in the United Kingdom [19], 12 years after the first
EPICure study, and the EXPRESS study in Sweden [20],
both covering infants born before 27 weeks. Given the
diversity of medical practices at the limits of viability,
extremely preterm birth should also be studied in other
countries. It appears important to us as well to study
births after 26–27 weeks because they are more numerous
and account for the majority of children with developmen-
tal deficits. This paper describes the objectives and methods
of the EPIPAGE 2 cohort study, a large population-based
prospective study launched in 2011 in France.
Objectives
The EPIPAGE 2 study aims to: 1) describe short- and
long-term outcomes in very and moderately preterm
babies and their families; 2) study changes in medical
practices and organization of care and assess their im-
pact on child health and development; and 3) explore
the etiology of preterm birth and identify early predic-
tors of health and developmental problems.
Methods/Design
Study design and population
EPIPAGE 2 is a population-based prospective study sched-
uled to follow children up to the age of 12 years. Eligible
participants include all infants live born or stillborn and
all terminations of pregnancy between 22 and 31 com-
pleted weeks of gestation in all the maternity units in 25
French regions (21 of the 22 metropolitan regions and 4
overseas regions) during the inclusion period. The only re-
gion that did not participate accounted for 18 415 births
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in 2011, i.e., 2.2% of all births in France. In addition, a
sample of moderate preterm births, i.e., births and late ter-
minations at 32–34 weeks, was included in the same re-
gions. The study began on March 28, 2011, and ended on
December 31, 2011. The population eligible for follow-up
includes all children alive at discharge from neonatal in-
tensive care or special units or maternity wards whose
parents have not declined to participate. This study will
also use a sample of children born at term for control pur-
poses. This group will be extracted from the population of
the Elfe study, a contemporary cohort with a 20-year
planned follow-up of 18 500 children born at or near term
in 2011, in 344 randomly selected public and private ma-
ternity units in metropolitan France (www.elfe-france.fr).
Information on the Elfe study is described elsewhere [21].
Sample size/power calculation
The sample size was calculated to obtain a number of
children at each week of gestation sufficient to 1) assess
the frequency of adverse events with reasonable preci-
sion, i.e., the estimated value must lie within 20% of the
true value (relative accuracy of 20%), 2) demonstrate
differences in prognosis between preterm and term in-
fants but also between preterm groups, with a statistical
power of 80%, and 3) develop specific projects for sub-
populations of very preterm babies. Table 1 reports the
numbers of children required to be included at birth
(live births only) and in the follow-up. Estimations were
based on the frequency of the main health and develop-
mental disorders expected in each gestational age range
[4-7]. Table 1 also reports the number of children in-
cluded in the study by gestational age groups.
Recruitment
Recruitment took place at birth in all maternity units of the
25 participating French regions, after the parents received
information about the study and agreed to participate. The
required number of infants was provided by an 8-month re-
cruitment period for extremely preterm births (22–
26 weeks), from March 28 to November 27, 2011, in 7 re-
gions (Alsace, Bourgogne, Guyane, Languedoc-Roussillon,
Limousin, Midi-Pyrénées, and Rhône-Alpes) and from
May 2 to December 31, 2011, in the remaining 18 regions
(Aquitaine, Auvergne, Basse-Normandie, Bretagne,
Centre, Champagne-Ardenne, Franche-Comté, Haute-
Normandie, Ile-de-France, Lorraine, Nord-Pas-de-
Calais, PACA-Corse, Pays de la Loire, Picardie,
Martinique, La Réunion, and Guadeloupe), and by a
6-month recruitment period for very preterm births (27–
31 weeks), from March 28 to September 25, 2011, in 7 re-
gions and from May 2 to October 30, 2011, in the
remaining 18. In addition, all children born at 32–34 weeks
were included for 5 weeks from May 2 to June 5, 2011.
During the study period, 8400 births (stillbirths and
live births) and terminations of pregnancy (TOP) were
registered in the EPIPAGE 2 cohort study: 3261 were
born extremely preterm (1081 (33.1%) TOP, 1050 (32.2%)
stillbirths and 1130 (34.7%) live births), 3744 very preterm
(292 (7.8%) TOP, 356 (9.5%) stillbirths and 3096 (82.7%)
live births), and 1395 moderately preterm (19 (1.4%) TOP,
36 (2.6%) stillbirths and 1340 (96.0%) live births). Seven
percent of the families refused to be included in the
study at the stage of data extraction/collection from
hospital records. However, status at birth, mortality, and
a few perinatal data (gestational age, birth weight, and
socioeconomic status) were available for them. Of the
4467 children discharged alive from intensive care and
eligible for follow-up, 4% of the families refused and 22
died before one-year of age. Finally, 4290 were included
in the follow-up.
In each region, a coordinating committee was set up
specifically for the implementation of the study at the
regional level. Contacts were identified in each maternity
ward and each neonatal unit to supervise inclusions and
Table 1 Required numbers of children to be included and numbers of children included
22-26 weeks 27-28 weeks 29-30 weeks 31 weeks Total 22–31 weeks 32-34 weeks
Expected % of all births (1) 0.15-0.20 0.20 0.25-0.30 0.40 2.0
Expected survival rates % (2) 50 80-85 90-95 95 98-99
Expected severe deficits among survivors % (3) 20 15 5 3-4 1-2
Number of children required for follow-up 450 750 900 800 2900 1200
Number of live births to be included 900 900 1000 850 3650 1200
Number of live births registered in EPIPAGE 2 1130 899 1265 932 4226 1340
Number of live births included in EPIPAGE 2
(parental agreement)
1054 857 1190 862 3963 1206
Number of survivors included in the follow-up 552 740 1146 836 3274 1193
(1)Estimated prevalence of births by gestational age categories.
(2)Estimated survival rates by gestational age categories.
(3)Estimated rates of severe deficits by gestational age categories.
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data collection. During the recruitment, members of the
regional coordinating committee visited all maternity
units to ensure the identification of all eligible children.
Data collection at birth
At birth and during the neonatal period, data were
collected in the maternity and neonatal units. They were
extracted from medical records and completed by ques-
tions to obstetrical and neonatal teams. The initial data
collected about the pregnancy and delivery are intended
to allow us to investigate specific pregnancy complica-
tions, including infectious, inflammatory, and vascular-
placental diseases, medication use up to the moment of
birth (tocolytics, magnesium sulfate, antenatal cortico-
steroids, and anesthesia), and decisions about termin-
ation of pregnancy, delivery, or limitations of care. The
neonatal component was designed to capture the child's
condition at birth, neonatal diseases, organization of
care and management after birth, treatment and medi-
cation (sedation, postnatal corticosteroids, etc.), and
abnormalities in early brain development and matur-
ation, assessed by imaging techniques. We collected data
on attitudes of care for extremely preterm births by
describing situations in which intensive care was limited
and palliative care provided at birth and situations where
intensive treatment was initiated, pursued, and subse-
quently limited. Mothers were interviewed in the neonatal
unit to obtain information about the family's social pos-
ition and the mother's perception of her prenatal man-
agement. Each mother also completed a self-administered
questionnaire assessing her mental health and the man-
agement of her baby in neonatal units, just before the
baby’s discharge.
Data management
Data extracted from maternity and neonatal records
were completed directly online, with a secure interface
for maintaining the confidentiality and privacy of data
and personal information. Completed maternal inter-
views and self-administered questionnaires were sent for
entry in the same dedicated database. Data entry and
validation were performed as a continuous process. Pro-
grams were run to check missing data and range of
responses.
Data collection about obstetric and neonatal units
Another part of the EPIPAGE 2 study focused on the
maternity and neonatal units that care for very preterm
children. We distributed questionnaires to the medical
teams of these units to collect data on their structural
characteristics, organization, and policies and practices
related to medical interventions and decision-making
processes. This data collection took place in 2012 in 402
maternity units where very preterm deliveries occurred
in 2011 and in 272 neonatal units. Ninety-one percent of
maternity units and 100% of neonatal units completed
the questionnaire.
Follow-up
We plan to collect follow-up information at corrected
age (CA) of 1 and 2 years and at 5, 8, and 12 years of
age. The follow-up at 1 year corrected age has just
ended. It comprised a questionnaire sent to the parents
collecting information on postneonatal care (hospital
admissions, medical visits, etc.), growth, respiratory dis-
eases, including bronchiolitis, and treatments, maternal
health, and the family’s social condition. At 2 year CA,
questionnaires are being sent to the parents and to the
physician providing care for the child. The questionnaire
to the parents investigates child development with stan-
dardized scales, i.e., the Stages and Ages Questionnaire,
the Modified-Checklist for Autism in Toddlers, and the
short form of the MacArthur Communicative Develop-
ment Inventory. It also collects data on child nutrition
and maternal health. Physicians are asked to complete a
short questionnaire on motor and sensory deficits. In re-
gions where formal follow-up networks have been set up
for the care of very preterm children, the 2-year (CA)
medical data will be provided by the network's reference
physicians.
Assessments of health status and development will be
performed in regional examination centers at 5, 8, and
12 years of age. These check-ups will include a complete
clinical examination and psychological tests and will
evaluate, using standardized tools:
– Growth, assessed by standardized anthropometric
measurements;
– Motor disorders, especially cerebral palsy and minor
neuromotor dysfunctions. Cerebral palsy will be
identified according to the diagnostic criteria
proposed by the Surveillance of Cerebral Palsy in
Europe (SCPE) network [22]. The Gross Motor
Classification System [23] and the Manual Ability
Classification System (MACS) [24] will be used
to assess functional abilities. A standardized
neurological examination will be used to explore fine
motor disorders.
– Cognitive functions, assessed by the intelligence
quotient (IQ), according to the principal validated
scales, i.e., the Wechsler Intelligence Scale for
Children (WISC-III or IV), Wechsler Preschool and
Primary Scales Intelligence (WPPSI) [25], or the
Kaufman Assessment Battery for Children Test [26].
Because these tools do not detect subtle disorders
in visuomotor, language, memory, or executive
functions, specific investigations will be conducted
for these functions.
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– Behavioral aspects of development, assessed by the
Strengths and Difficulties Questionnaire [27], which
is the most widely used and validated behavioral
scale in France. This scale will be completed by an
assessment of children’s symptoms of anxiety and
depression.
– Quality of life (QoL) with a self-administered
questionnaire, KIDSCREEN [28], and with the Child
Health Questionnaire (CHQ), a generic instrument
for measuring objective QoL and health status for
children, both designed for the general population
and children with various diseases.
At the ages of 5, 8, and 12 years, we will also collect
data about educational achievement, school difficulties,
special support at school, and special care outside
school. The results of the national tests given at 12 years
will also be collected.
Postneonatal care has evolved, and programs exist that
aim to improve very preterm children’s prognosis. The
implementation of these new practices need to be
assessed in detail, however, to measure all their effects,
beneficial or not, especially over the long term. There
are various proposed interventions, which remain poorly
described. Their description is the first step planned,
and their evaluation, the second, because the level of evi-
dence of interventions in this area is low [29].
Data analysis
All statistical analyses must be pre-specified and ap-
proved by the steering committee. Participation refusals
and children lost to follow-up will be compared with
participating subjects for recorded perinatal factors such
as gestational age, status at birth, neonatal care level,
and region. Analyses will take place after the completion
of each phase (neonatal period, ages 1 (CA), 2 (CA), 5,
8, and 12 years). A number of analyses will utilize the
strength of the longitudinal design and multilevel multi-
variate statistical modeling methods to determine not
only the neonatal predictors of outcomes, but also com-
plications, care, and social environment over time.
Ethics
Recruitment and data collection occurred only after fam-
ilies had received information and agreed to participate in
the study. The data collected at birth and during the
follow-up phases were and will continue to be totally
anonymized. The only nominative file is the one contain-
ing the family addresses and contact information — the
data that make the follow-up possible, but which are com-
pletely separated from all survey data. As required by
French law and regulations, this study was approved by
the national data protection authority (Commission Natio-
nale de l’Informatique et des Libertés, CNIL n°911009)
and by the appropriate ethics committees, i.e., the advisory
committee on the treatment of personal health data for
research purposes (CCTIRS: Comité Consultatif sur le
Traitement de l'Information en matière de Recherche,
approval granted November 18, 2010; reference number
10.626) and the committee for the protection of people
participating in biomedical research (CPP: Comité de
Protection des Personnes, approval granted March 18,
2011, reference CPP SC-2873).
Project governance
The governance is consistent with the charter set forth
by the French Institute for Public Health Research,
which outlines the rights and responsibilities of research
teams working together with very large cohorts for
health research (www.iresp.net). The project is coordi-
nated at two levels: 1) at the national level by a Steering
Committee responsible for the scientific project and
organization of the study; this committee includes epide-
miologists, pediatricians, obstetricians, and members of
perinatal networks, from all participating regions of
France; and 2) at the regional level, with a coordinating
committee set up in each region specifically to imple-
ment the study there.
Additional projects
EPIPAGE 2 has been designed to allow various research
groups to develop additional projects aimed at inves-
tigating specific hypotheses among subsamples of the
cohort by collecting specific data in addition to the core
cohort data. Eight additional projects are already under-
way in the fields of placental histology (CHORHIST),
genetics (BIOPAG), ethics, painful procedures in neo-
natal units (EPIPPAIN 2), cerebral imaging (EPIRMEX),
nutrition (EPINUTRI and EPIFLORE), and mother-
infant attachment (OLIMPE) (Table 2).
Collaborative projects
The EPIPAGE 2 cohort study is associated with a European
project, EPICE (Effective Perinatal Intensive Care in
Europe, www.epiceproject.eu), that is studying very pre-
term children born in 19 European regions in 2011–12,
including three regions in France (Burgundy, Ile-de-
France, and Nord-Pas de Calais). Its aim is to improve
our understanding of how treatments or interventions
that have been demonstrated to be effective are or not
used in medical practice and what obstacles impede
their widespread use. The data needed for the EPICE
study for the three French regions is being collected as
part of EPIPAGE 2. EPIPAGE 2 is also associated with
the ELFE study (www.elfe-france.fr), a contemporary
cohort of babies born at 33 weeks or more. EPIPAGE 2
and ELFE are the two components of the RECONAI
platform, a French research platform for birth cohorts.
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Information about very and moderately preterm births
is being collected through EPIPAGE 2, and data about
late preterm and term births through Elfe. EPIPAGE 2
and ELFE together will make it possible to study the events
that influence development, health, and socialization of
children from the fetal period through adolescence. The
results will guide obstetric and pediatric care and public
policy-making in the domains of family and childhood.
Discussion
Very preterm children and their families face a range of
medical, psychological, and social problems that raise spe-
cific questions at birth and thereafter. The need for infor-
mation on the prevalence, causes, and consequences of
preterm birth requires large population-based cohort
studies with a long-term follow-up, especially in France,
where the most recent detailed data about very preterm
births date back to the EPIPAGE 1 study, 15 years ago.
Especially with its associated projects, the EPIPAGE 2
study, which brings together a cohort of 4500 preterm
children, offers an original approach. The establishment
and follow-up of this cohort and the collection of such
diverse data (social, clinical, biological, and imaging) will
increase our understanding of how to 1) improve the care
and management of preterm children, 2) identify predic-
tors of long-term outcomes in various components of
health in the light of recent progress in medical practices,
particularly in the field of brain imaging, and 3) enhance
both the organization of care and decisions about the
continuation of treatment. Our findings should provide
evidence to design new strategies of management and pre-
vention and to inform trials of interventions evaluating
their impact. It will also enable research teams to access
this information and to test new hypotheses in this at-risk
population.
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Table 2 Projects associated with EPIPAGE 2
Projects (Investigator(s)) Objectives
CHORHIST (G Kayem, D Subtil, Obstetricians) To identify histological chorioamnionitis by examining the placentas of all children
born between 22 and 31 weeks in 23 perinatal centers and to study it in relation to
short- and long-term outcomes (N = 1406).
BIOPAG (P Boileau, Pediatrician, V. Benhammou, Biologist) To determine genetic markers of mother and child and their relation to short- and
long-term outcomes. Maternal and cord blood samples (DNA, RNA) were collected
at birth in 14 perinatal centers (N = 149).
ETHICS (L Foix-L’Hélias, Pediatrician, Epidemiologist) To assess situations in which limitation of care is discussed during prenatal or neonatal
care and to analyze the decision-making processes that led to limitations, withdrawals,
or substitutions of palliative care, or continuation of care among extremely preterm
infants (live born, stillborn, and pregnancy terminations < 27 weeks) born in 18 perinatal
centers (N = 419).
EPIPPAIN 2 (R Carbajal, Pediatrician) To analyze painful procedures in neonatal intensive care units and their relation to child
health and development in all infants born very preterm in Paris-area level III facilities
and included in the EPIPAGE 2 cohort (N = 562).
EPIRMEX (E Saliba, Pediatrician) To study executive functions and language development during early childhood as a
function of abnormalities detected by MRI at term among babies born at gestation
ages of 26 to 31 weeks in 15 perinatal centers where conventional and advanced MRI
techniques (3D MRI for the volume measurements, diffusion tensor images for tractography
analysis) were available (N = 582).
EPIFLORE (MJ Butel, Microbiologist) To study the development of the intestinal microbiota and to analyze the associations
between these abnormalities and diseases of early childhood, childhood, and adolescence
(e.g., allergies, metabolic syndrome, and diabetes) among very preterm children born in 19
perinatal centers (N = 728).
EPINUTRI (A Lapillonne, Pediatrician) To study associations between neonatal nutrient intake (of polyunsaturated fatty acids,
iron, and milk, with breastfeeding considered separately) and child development in a
sample of very preterm infants, i.e., 22–31 weeks born in the Paris area (N = 325).
OLIMPE (JB Muller, Pediatrician, C Arnaud, Epidemiologist,
C Lebeaux, Pediatrician, Epidemiologist)
To explore mother-infant attachment at hospital discharge and at 6 months among
very preterm children born in 12 perinatal centers to 1) identify factors linked to the
child's health status and to the organization of the neonatal unit that might influence
interactions between mothers and their children; and 2) investigate whether the quality
of early mother-infant interactions is associated with further child development and
behaviour (N = 167).
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